Droperidol on Prevention of Cannabis Hyperemesis Syndrome

Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

Patients presenting to the Emergency Department with nausea, vomiting and/or abdominal pain with a significant history of cannabis use and symptoms in a cyclic pattern will be assessed for study inclusion. After given written informed consent, patients will be treated with droperidol and diphenhydramine and symptoms will be assessed using a visual analog scale at time intervals up to 120 minutes. Patient will then be contacted at 24 and 48 hour intervals to assess symptoms on the same scale. This is a multicenter, prospective interventional study with results compared to a historical cohort using haloperidol.

Inclusion Criteria:

• aged 18 years of age or older and presenting with cannabis hyperemesis syndrome requiring intravenous medication.

Exclusion Criteria:

• any patient with a contraindication to the use of droperidol
• Corrected QT interval on ECG greater than 440 milliseconds for males and greater than 450 milliseconds for females
• any prisoners
• pregnant females.